2015
Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome
Knauert M, Naik S, Gillespie MB, Kryger M. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World Journal Of Otorhinolaryngology - Head And Neck Surgery 2015, 1: 17-27. PMID: 29204536, PMCID: PMC5698527, DOI: 10.1016/j.wjorl.2015.08.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsObstructive sleep apnea syndromeSleep apnea syndromeUntreated obstructive sleep apnea syndromeApnea syndromeEffective therapyPoor patient acceptanceStart date restrictionLack of diagnosisSignificant economic burdenEnglish-language studiesExcessive daytimeSleep apneaPatient acceptanceCardiovascular diseaseClinical consequencesDate restrictionsEconomic burdenMetabolic diseasesPubMed databaseAbnormal physiologySyndromeTherapyLack of accessDiseaseTreatment
1987
Trial of a Dopaminergic Antidepressant in Obstructive Sleep Apnea
George C, West P, Millar T, Kryger M. Trial of a Dopaminergic Antidepressant in Obstructive Sleep Apnea. Sleep 1987, 10: 180-183. PMID: 3589330, DOI: 10.1093/sleep/10.2.180.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaAnticholinergic side effectsSleep apneaSide effectsImmune hemolytic anemiaCentral nervous system stimulant propertiesPharmacologic therapyUseful therapyEffective therapyUnacceptable incidenceDopaminergic antidepressantsHemolytic anemiaNomifensineRigorous scientific testingStimulant propertiesTherapyApneaAntidepressantsPatientsAnemiaDopaminergicIncidenceTrialsScientific testingProtriptyline